RESPONSE, RESISTANCE AND METASTASIS OF LOCALLY-ADVANCED BREAST CANCER (LABC)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一个研究局部晚期乳腺癌(LABC)的方案，目的是了解癌症从局部疾病到转移的进展。将对LABC进行研究，以确定对紫杉醇和放射同时有效的疾病是否在遗传、免疫或分子上与无反应并进展为转移性疾病的疾病不同。这项研究将广泛研究这种疾病的行为、文化、流行病学(包括危险因素)、遗传、免疫学、分子和(可能)种族方面的问题。将有300名患者入选，其中100人在纽约大学，其他人在南非和墨西哥。参与试验的个人将被收集样本，用于诊断和随后的病理、基因组和分子生物学目的。采集样本和将其存入银行以供日后使用，均须取得同意。这项研究的动机是观察到对初级化疗的病理反应正在成为生存的替代终点。LABC提供了一个很好的机会来研究疾病进展到转移的生物学相关性，因为LABC记录了细胞脱落到循环中，但这还不足以触发远程疾病的发展。对局部肿瘤对化疗和放疗的反应的研究有望帮助评估根据肿瘤特征量身定做的后续治疗。LABC是一种“服务不足者的疾病”，处于不利地位的人可能会推迟寻求(或获得)帮助，直到疾病恶化。这项研究的国际站点提供了接触属于这一类别的人群的途径，并允许研究该病的广泛潜在因素。肿瘤及其周围组织的分子和基因图谱有望为研究细胞群体的转化提供机会。流行病学和文化信息将使适合不同人群的诊断和治疗战略成为可能。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a protocol studying locally advanced breast cancer (LABC) with the goal of understanding the progression of cancer from local disease to metastasis. LABC will be studied to see whether disease that responds to concurrent Paclitaxel and radiation is genetically, immunologically or molecularly distinct from that which is unresponsive and progresses to metastatic disease. The study will broadly study behavioral, cultural, epidemiological (including risk factors), genetic, immunological, molecular and (possibly) ethnic aspects of the disease. Three hundred patients will be enrolled, 100 at NYU and others in South Africa and Mexico. Individuals enrolled in the trial will have samples collected that will be used for both diagnostic and subsequent pathological, genomic and molecular biological purposes. Consent is requested for specimen collection and banking for subsequent use. The study is motivated by the observation that the pathological response to primary chemotherapy is emerging as a surrogate endpoint for survival. LABC provides a good opportunity to study the biological correlates of disease progression to metastasis, since shedding of cells into the circulation is documented in LABC, but this is not sufficient to trigger the development of remote disease. A study of the response of the local tumor to chemotherapy and radiation is expected to help evaluate subsequent treatment tailored to the tumor characteristics. LABC is a "disease of the underserved," with disadvantaged individuals likely to delay seeking (or finding access to) help until the disease has progressed. International sites for this study provide access to populations that fall into this category and permit a broad range of potential factors in the disease to be studied. The molecular and genetic profiles of the tumors and surrounding tissues will hopefully provide a chance to study the transformation of the cell populations. Epidemiological and cultural information will permit diagnosis and treatment strategies appropriate for different populations.